These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 12450450)

  • 1. Variability of insulin absorption and insulin action.
    Heinemann L
    Diabetes Technol Ther; 2002; 4(5):673-82. PubMed ID: 12450450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intra-individual variability of the metabolic effect of inhaled insulin together with an absorption enhancer.
    Heinemann L; Klappoth W; Rave K; Hompesch B; Linkeschowa R; Heise T
    Diabetes Care; 2000 Sep; 23(9):1343-7. PubMed ID: 10977030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New ways of insulin delivery.
    Heinemann L
    Int J Clin Pract Suppl; 2011 Feb; (170):31-46. PubMed ID: 21323811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subcutaneous absorption of insulin in insulin-dependent diabetic patients. Influence of species, physico-chemical properties of insulin and physiological factors.
    Hildebrandt P
    Dan Med Bull; 1991 Aug; 38(4):337-46. PubMed ID: 1914533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Variability of the metabolic effect of soluble insulin and the rapid-acting insulin analog insulin aspart.
    Heinemann L; Weyer C; Rauhaus M; Heinrichs S; Heise T
    Diabetes Care; 1998 Nov; 21(11):1910-4. PubMed ID: 9802742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhaled human insulin: new drug. No short-term advantages, too many unknowns in the long term.
    Prescrire Int; 2006 Dec; 15(86):203-9. PubMed ID: 17165235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin formulations--a review.
    Gualandi-Signorini AM; Giorgi G
    Eur Rev Med Pharmacol Sci; 2001; 5(3):73-83. PubMed ID: 12004916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proportional dose-response relationship and lower within-patient variability of insulin detemir and NPH insulin in subjects with type 1 diabetes mellitus.
    Wutte A; Plank J; Bodenlenz M; Magnes C; Regittnig W; Sinner F; Rønn B; Zdravkovic M; Pieber TR
    Exp Clin Endocrinol Diabetes; 2007 Jul; 115(7):461-7. PubMed ID: 17647145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intramuscular versus subcutaneous injection of soluble and lispro insulin: comparison of metabolic effects in healthy subjects.
    Rave K; Heise T; Weyer C; Herrnberger J; Bender R; Hirschberger S; Heinemann L
    Diabet Med; 1998 Sep; 15(9):747-51. PubMed ID: 9737803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin detemir under steady-state conditions: no accumulation and constant metabolic effect over time with twice daily administration in subjects with Type 1 diabetes.
    Bott S; Tusek C; Jacobsen LV; Endahl L; Draeger E; Kapitza C; Heise T
    Diabet Med; 2006 May; 23(5):522-8. PubMed ID: 16681561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Technosphere/Insulin--proof of concept study with a new insulin formulation for pulmonary delivery.
    Steiner S; Pfützner A; Wilson BR; Harzer O; Heinemann L; Rave K
    Exp Clin Endocrinol Diabetes; 2002 Jan; 110(1):17-21. PubMed ID: 11835120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New ways of insulin delivery.
    Heinemann L
    Int J Clin Pract Suppl; 2010 Feb; (166):29-40. PubMed ID: 20377662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Measurement of insulin absorption and insulin action.
    Heinemann L; Anderson JH
    Diabetes Technol Ther; 2004 Oct; 6(5):698-718. PubMed ID: 15628821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical strategies for controlling peaks and valleys: type 1 diabetes.
    Bolli GB
    Int J Clin Pract Suppl; 2002 Jul; (129):65-74. PubMed ID: 12166610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Absorption and metabolic effect of inhaled insulin: intrapatient variability after inhalation via the Aerodose insulin inhaler in patients with type 2 diabetes.
    Perera AD; Kapitza C; Nosek L; Fishman RS; Shapiro DA; Heise T; Heinemann L
    Diabetes Care; 2002 Dec; 25(12):2276-81. PubMed ID: 12453973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes.
    Klein O; Lynge J; Endahl L; Damholt B; Nosek L; Heise T
    Diabetes Obes Metab; 2007 May; 9(3):290-9. PubMed ID: 17391154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose-response relationships of inhaled insulin delivered via the Aerodose insulin inhaler and subcutaneously injected insulin in patients with type 2 diabetes.
    Kim D; Mudaliar S; Chinnapongse S; Chu N; Boies SM; Davis T; Perera AD; Fishman RS; Shapiro DA; Henry R
    Diabetes Care; 2003 Oct; 26(10):2842-7. PubMed ID: 14514589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Technosphere/Insulin--a new approach for effective delivery of human insulin via the pulmonary route.
    Pfützner A; Mann AE; Steiner SS
    Diabetes Technol Ther; 2002; 4(5):589-94. PubMed ID: 12450439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [From the concept of fast acting analogs to the properties of the insulin Lispro].
    Selam JL
    Diabetes Metab; 1997 Sep; 23 Suppl 3():45-9. PubMed ID: 9410552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Time-action profile of inhaled insulin.
    Heinemann L; Traut T; Heise T
    Diabet Med; 1997 Jan; 14(1):63-72. PubMed ID: 9017356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.